Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial

4 months ago

Gilead’s experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. 

More Stories

Microsoft CEO Nadella asked for pay reduction after security slip, but total comp still rose 63%

1 hour ago

Hurricane Helene damage estimated at $53bn, as US relief bill passes

1 hour ago

Why is Israel targeting Al Jazeera correspondents in Gaza?

2 hours ago

Leave a Reply

Your email address will not be published. Required fields are marked *

You may have missed

Kwara’s demolition drive: Development or destruction? By Abdulraheem O. Abdulraheem

1 hour ago

Disruptive innovations and AI: Opportunities and challenges for Nigeria, By Wale Bakare

1 hour ago

Jonathan to lead AU election mission to Botswana, departs Nigeria

1 hour ago

Tinubu reiterates commitment to revamp Nigeria’s livestock sector

1 hour ago

Nigerian bureau launches investigation into helicopter crash

1 hour ago